P483 Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease
ECCO'20 Vienna
2020
P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience
ECCO'20 Vienna
2020
P485 Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch
ECCO'20 Vienna
2020
P487 Development and validation of a new patient-reported outcome measure for Crohn’s perianal fistula: Crohn’s anal fistula quality-of-life (CAF-QoL) scale
ECCO'20 Vienna
2020
P488 How reliable is the online medical information on paediatric inflammatory bowel diseases?
ECCO'20 Vienna
2020
P489 Are patients with inflammatory bowel disease receiving an adequate immunisation?
ECCO'20 Vienna
2020
P490 Assessment of body weight changes in patients with inflammatory bowel diseases initiating biologic therapy: A prospective cohort study
ECCO'20 Vienna
2020
P491 De-escalation of dose-intensified anti-TNF therapy in IBD patients in sustained deep remission
ECCO'20 Vienna
2020
P492 Use of bowel ultrasound to assess disease activity in Crohn’s disease patients after induction therapy with infliximab
ECCO'20 Vienna
2020
P493 Segmental colectomy vs. extended colectomy for colonic Crohn’s disease: results from 112 consecutive patients
ECCO'20 Vienna
2020
P494 The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
ECCO'20 Vienna
2020
P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease
ECCO'20 Vienna
2020
P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease
ECCO'20 Vienna
2020
P498 Loss of response of anti-TNF in Crohn’s disease patients single-centre experience
ECCO'20 Vienna
2020